2021 has been a significant year for Anatara Lifesciences Limited (ASX:ANR), as we made steps towards progressing our human health products towards clinical trials, successfully completed animal health studies and progressed licensing discussions.
The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 30 September 2021.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has received Human Research Ethics Committee (HREC) approval from The Royal Melbourne Hospital.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has agreed revised terms with cornerstone investor Mr Aiden Jiang for the draw down of $1,500,000 from a previously agreed convertible loan facility.
VGI Health Technology Limited (NSX:VTL) is pleased to present the FY21 Annual Report to Shareholders.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that eminent hepatologist, Professor Darrell H.G. Crawford, has been appointed to its Scientific Advisory Board (SAB).
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has appointed Gallipoli Medical Research Foundation (GMRF) as a clinical study site for Phase II Clinical Study.
